Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerGlobeNewsWire • 12/09/20
Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial ResultsGlobeNewsWire • 12/09/20
Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9thGlobeNewsWire • 11/23/20
Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate CancerGlobeNewsWire • 09/29/20
Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate CancerGlobeNewsWire • 09/18/20
Veru to Participate and Present at Four Upcoming Healthcare Investor ConferencesGlobeNewsWire • 09/09/20
Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/13/20
VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19GlobeNewsWire • 08/04/20
Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13thGlobeNewsWire • 07/30/20
Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral PresentationGlobeNewsWire • 07/27/20
Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate CancerGlobeNewsWire • 07/23/20
Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19GlobeNewsWire • 06/19/20
Veru Inc. (VERU) CEO Mitchell Steiner on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%GlobeNewsWire • 05/13/20
Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19GlobeNewsWire • 05/12/20
Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical ProgramGlobeNewsWire • 05/05/20
Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer DrugGlobeNewsWire • 02/26/20